Loading company…
Orbus Therapeutics develops and sells rare disease treatments, focusing on eflornithine, from Palo Alto, US.
Founded in 2012 and based in Palo Alto, US, Orbus Therapeutics has secured 4 funding deals. Its core product is eflornithine, a treatment for life-threatening conditions including grade 3 astrocytoma. Its Series A round completed in July 2020 raised USD 10.00 mn from Abingworth, Adams Street Partners, H.I.G. BioHealth Partners and Longitude Capital. Jason Levin and Victor Levin are its founders.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in